{"id":"eu-sourced-avastin","safety":{"commonSideEffects":[{"rate":"20–40%","effect":"Hypertension"},{"rate":"20–30%","effect":"Proteinuria"},{"rate":"5–15%","effect":"Hemorrhage"},{"rate":"5–10%","effect":"Thromboembolic events"},{"rate":"1–2%","effect":"Gastrointestinal perforation"},{"rate":"5–10%","effect":"Wound healing complications"},{"rate":"15–25%","effect":"Fatigue"},{"rate":"10–20%","effect":"Diarrhea"}]},"_chembl":null,"_fixedAt":"2026-03-30T16:07:18.464308","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab binds to circulating VEGF, a key signaling protein that promotes angiogenesis (new blood vessel growth). By neutralizing VEGF, the drug inhibits the formation of new blood vessels that tumors require to grow and metastasize. This anti-angiogenic mechanism reduces tumor perfusion and can slow or halt tumor progression.","oneSentence":"Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:52.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"},{"name":"Glioblastoma"},{"name":"Metastatic renal cell carcinoma"},{"name":"Ovarian cancer"}]},"_fixedFields":["pubmed(2)"],"trialDetails":[{"nctId":"NCT03483649","phase":"PHASE1","title":"Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male Subjects","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2017-04-21","conditions":"Healthy Male Subjects","enrollment":208},{"nctId":"NCT02453672","phase":"PHASE1","title":"Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2015-04","conditions":"Healthy","enrollment":119},{"nctId":"NCT03030430","phase":"PHASE1","title":"Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2016-03-15","conditions":"NSCLC","enrollment":128},{"nctId":"NCT03131700","phase":"PHASE1","title":"Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator","status":"WITHDRAWN","sponsor":"TRPHARM","startDate":"2017-12","conditions":"Healthy","enrollment":""},{"nctId":"NCT02747823","phase":"PHASE1","title":"PK Bioequivalence Single-dose Safety Tolerability Study in Healthy Male Volunteers to Compare CBT124 & Avastin(EU&US)","status":"UNKNOWN","sponsor":"Cipla BioTec Pvt. Ltd.","startDate":"2016-06","conditions":"Healthy","enrollment":150},{"nctId":"NCT02879097","phase":"PHASE3","title":"Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC","status":"UNKNOWN","sponsor":"Cipla BioTec Pvt. Ltd.","startDate":"2016-12","conditions":"Non-Small Cell Lung Carcinoma","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"recentPublications":[{"date":"2023 Nov","pmid":"37935428","title":"Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.","journal":"Cancer medicine"},{"date":"2019 Jun","pmid":"31016568","title":"A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin(®)) in Healthy Male Subjects.","journal":"BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"EU-sourced Avastin®","genericName":"EU-sourced Avastin®","companyName":"Cipla BioTec Pvt. Ltd.","companyId":"cipla-biotec-pvt-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients. Used for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}